NewEdge Advisors’s AIM ImmunoTech AIM Stock Holding History

NewEdge Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,000	Closed	-$2.92K	–	4426
2026 Q1	$2.92K	Buy	+5,000	New	+$5.07K	﹤0.01%	3720
2024 Q4	–	Hold	0	–	–	–	4091
2024 Q3	–	Hold	0	–	–	–	4003
2024 Q2	–	Hold	0	–	–	–	4071
2024 Q1	–	Hold	0	–	–	–	4014
2023 Q4	–	Hold	0	–	–	–	3937
2023 Q3	–	Hold	0	–	–	–	3727
2023 Q2	–	Hold	0	–	–	–	3477

Other funds holding AIM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

NewEdge Advisors's AIM Position: Q2 2026 in Review

NewEdge Advisors sold out of AIM ImmunoTech (AIM) in Q2 2026, closing a stake of 5,000 shares — an estimated $2.92K sold.

NewEdge Advisors first reported a position in AIM in Q1 2026 and held it in 1 quarter. The position peaked at $2.92K in Q1 2026. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

NewEdge Advisors reported no remaining AIM ImmunoTech position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 5,000 AIM ImmunoTech shares in Q2 2026, an estimated $2.92K.
NewEdge Advisors first reported a position in AIM ImmunoTech in Q1 2026 and held it in 1 quarter.
NewEdge Advisors's AIM ImmunoTech position peaked at $2.92K in Q1 2026.
18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.